The Role of Vascular Endothelial Growth Factor in Angiogenesis

  title={The Role of Vascular Endothelial Growth Factor in Angiogenesis},
  author={Napoleone Ferrara and Hans-Peter Gerber},
  journal={Acta Haematologica},
  pages={148 - 156}
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an angiogenic inducer as well as a mediator of vascular permeability. The biological effects of VEGF are mediated by two tyrosine kinase receptors, Flt-1 (VEGFr-1) and KDR (VEGFR-2). VEGF is essential for developmental angiogenesis and is also required for female reproductive functions and endochondral bone formation. Substantial evidence also implicates VEGF in tumors and intraocular neovascular syndromes… 

Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis.

This review focuses on vascular endothelial growth factors (VEGF), a group of structurally-related proteins that serve as key growth factors for tumor-associated angiogenesis. Pathways induced by

Vascular endothelial growth factor as a target opportunity in hematological malignancies

Evidence suggests that VEGF is also a survival factor for endothelial cells and perhaps tumor cells, and the development of a number of agents to target this system that are currently under clinical investigation is suggested.

Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.

It is important to understand the physiology of VEGF and PDGF and their receptors as well as their roles in malignancies in order to develop antiangiogenic strategies for the treatment of malignant disease.

Vascular Endothelial Growth Factor Receptor Antagonist - A Target for Treating Inflammatory Disease

The present review of literature was done to check the influence of the main angiogenic factor vascular endothelial growth factor in the various physiological and pathological conditions like growth,

Bone marrow angiogenesis in multiple myeloma: closing in on the loop.

Overall, these studies suggest that induction of angiogenesis is a feature of, and possibly important in the transformation of MGUS to myeloma, and in the progression of early stageMyeloma to advanced, refractory disease.

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

In conclusion, VEGF is required for growth and proliferation of glomerular and peritubular endothelial cells and may contribute to recovery in other forms of renal diseases.

Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB

The neuronal expression of both VEGFA and VEGFB, together with their specific receptors in FCD, suggests autocrine/paracrine effects on dysplastic neurons and could play a role in the development of F CD, preventing the death of abnormal neuronal cells.

VEGF: an Essential Mediator of Both Angiogenesis and Endochondral Ossification

Current findings on endochondral ossification are discussed, with emphasis on VEGF-A action in osteoblasts,chondroblasts, and chondroclasts/osteoclasts and regulatory mechanisms involving oxygen tension, and some growth factors and hormones.



The biology of vascular endothelial growth factor.

The establishment of a vascular supply is required for organ development and differentiation as well as for tissue repair and reproductive functions in the adult1. Neovascularization (angiogenesis)

Role of vascular endothelial growth factor in the regulation of angiogenesis.

  • N. Ferrara
  • Biology, Medicine
    Kidney international
  • 1999
Compelling evidence indicates that vascular endothelial growth factor (VEGF) is a fundamental regulator of normal and abnormal angiogenesis and its inactivation during early postnatal life results in the suppression of glomerular development and kidney failure.

Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

The results raise the possibility that VEGF may play a role in the growth of hematopoietic neoplasms such as multiple myeloma through either a paracrine or an autocrine mechanism.

Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis.

It is proposed that excessive expression of VEGF during gonadotropin-induced ovulation may contribute to the development of ovarian hyperstimulation syndromes by virtue of the vascular permeabilization activity of this factor.

Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1.

These data are the first to show a direct effect of VEGF on SMCs, and suggest SMC-derived MMPs may be an additional source of proteases to digest vascular basement membrane, which is a crucial step in the initial stage of angiogenesis.

Clinical applications of angiogenic growth factors and their inhibitors

Inhibition of the action of key regulators of angiogenesis, such as VEGF, constitutes a promising approach for the treatment of solid tumors and intraocular neovascular syndromes.

Vascular endothelial growth factor is a secreted angiogenic mitogen.

DNA sequencing suggests the existence of several molecular species of VEGF, a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis in vivo.

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

Findings show that flt encodes a receptor for VEGF-VPF, a factor that induces vascular permeability when injected in the guinea pig skin and stimulates endothelial cell proliferation.

Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia.

A role for VEGF-B in the development or function of coronary vasculature is revealed and potential clinical use in therapeutic angiogenesis is suggested.

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

It is demonstrated that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.